THE PLAIN-LANGUAGE EXPLAINER
What Is Carphedon?
Carphedon is the original name of phenylpiracetam — a Soviet-developed racetam with a cosmonaut-era origin, a stimulant mechanism, and a naming history that confuses almost everyone who searches for it. This page fixes the naming, the chemistry and the family position, with the primary sources attached. Nothing here is medical advice.
First, the molecule itself
Phenylpiracetam is 2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide — formula C12H14N2O2, molecular weight 218.25, CAS 77472-70-9, PubChem CID 132441, UNII-99QW5JU66Y. Structurally it is piracetam (2-oxo-1-pyrrolidine acetamide) with a phenyl ring added at the 4-position of the pyrrolidinone ring; reviews also class it as a beta-substituted GABA derivative.[1][3][35]
That 4-position carbon is a stereocentre, and it matters: the marketed drug is the racemate — an equal mixture of the R and S enantiomers — while the pharmacology splits between them. The R-enantiomer carries the dopamine-transporter activity and improves memory in rodent passive-avoidance testing; the S-enantiomer does not, yet reduces weight gain in obese rodents without stimulating movement. Merz Pharmaceuticals gave the enantiomers code names: MRZ-9547 (R) and MRZ-9546 (S).[7][8][9]
The naming chain — why one drug has five names
Searching the literature on this molecule means searching five names. The chain below is the documented sequence; who personally coined “carphedon” is not recorded in any accessible source, and this site does not guess.
1980
The synthesis paper
Glozman, Morozov, Zhmurenko and Zagorevskii publish the founding synthesis in Khimiko-Farmatsevticheskii Zhurnal — the earliest located reference.[2]
1983
“4-phenylpiracetam”
The first pharmacological description names it plainly: “a new phenyl analog of piracetam — 4-phenylpiracetam”.[3]
1980s–90s
carphedon
The development-programme name (карфедон; also carphedone, karfedon). A Korean doping-analysis paper still titles the drug “carphedon” in 1999.[4]
1990s–2000s
phenylpiracetam · Phenotropil
The research literature settles on phenylpiracetam; Russian pharmacies sell Phenotropil (later also Actitropil).[23]
~2023 →
fonturacetam
The WHO international nonproprietary name enters the indexed literature — and WADA’s list now reads “Fonturacetam [4-phenylpiracetam (carphedon)]”.[29]
One nuance the record leaves open: the INN status of fonturacetam is confirmed (PubChem carries “Fonturacetam [INN]”), but the exact WHO list and year of adoption were not confirmed against the primary WHO document in our verification pass.[1]
Where it came from
Phenylpiracetam was developed at the Institute of Biomedical Problems (IBMP) — the Soviet and Russian space-medicine institute — as a new-generation psychostimulant intended to increase the mental and physical performance of cosmonauts at various stages of space flight. The later Russian Phenotropil literature is co-authored by psychopharmacologist V.I. Akhapkina, consistent with her leading the programme at IBMP.[5][6]
The full origin story — including the parts of the legend that do not survive verification, like the Mir medical-kit quote and the Chernobyl-liquidator claim — is on the history page, with the verified and the anecdotal kept visibly separate.
Its place in the racetam family
Piracetam is the parent — the 1960s UCB compound for which Corneliu Giurgea coined the word “nootropic”. The family shares the 2-oxo-1-pyrrolidine acetamide scaffold; the standard survey groups phenylpiracetam with piracetam, oxiracetam, aniracetam and pramiracetam among the members used in humans, while levetiracetam and brivaracetam became SV2A antiepileptics. Phenylpiracetam is described as more potent than piracetam and used for a wider range of indications — and it is the only racetam with a stimulant’s regulatory footprint.[12][13]
The honest family caveat: for piracetam itself, the Cochrane review of dementia and cognitive impairment found that the published evidence does not support its use, and the modes of action of most racetams “remain an enigma”. Carphedon inherits that scepticism — the comparison page covers it in full.[25][12]
What it is today
A prescription-only medicine in Russia (Phenotropil, Actitropil); not authorised for human use by any health authority in the EU or Australia; an unapproved drug in the United States; and a prohibited in-competition stimulant in sport since 1998 — the first nootropic ever listed, and still the only racetam on the WADA Prohibited List.[27][26][28]
Questions about any medicine belong with a qualified clinician who knows the full clinical picture. This site makes the published evidence readable; it does not direct anyone’s care, and nothing here is for sale.